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Abstract
Background: LINE-1 (L1) retrotransposons are a notable endogenous source of mutagenesis in mammals.
Notably, cancer cells can support unusual L1 retrotransposition and L1-associated sequence rearrangement
mechanisms following DNA damage. Recent reports suggest that L1 is mobile in epithelial tumours and
neural cells but, paradoxically, not in brain cancers.
Results: Here, using retrotransposon capture sequencing (RC-seq), we surveyed L1 mutations in 14 tumours classified
as glioblastoma multiforme (GBM) or as a lower grade glioma. In four GBM tumours, we characterised one probable
endonuclease-independent L1 insertion, two L1-associated rearrangements and one likely Alu-Alu recombination event
adjacent to an L1. These mutations included PCR validated intronic events in MeCP2 and EGFR. Despite sequencing L1
integration sites at up to 250× depth by RC-seq, we found no tumour-specific, endonuclease-dependent L1 insertions.
Whole genome sequencing analysis of the tumours carrying the MeCP2 and EGFR L1 mutations also revealed no
endonuclease-dependent L1 insertions. In a complementary in vitro assay, wild-type and endonuclease mutant L1
reporter constructs each mobilised very inefficiently in four cultured GBM cell lines.
Conclusions: These experiments altogether highlight the consistent absence of canonical L1 retrotransposition
in GBM tumours and cultured cell lines, as well as atypical L1-associated sequence rearrangements following
DNA damage in vivo.
Background
Glioblastoma multiforme (GBM) is the most common
and aggressive brain tumour in adults [1]. Ninety-five
percent of diagnosed GBM tumours originate de novo
(primary GBM), while the remainder progress from a
lower grade glioma (secondary GBM) [2]. Primary and
secondary GBM tumours are histologically indistinguish-
able [3]. To date, genomic analyses have elucidated
somatic mutations and intra-tumoural heterogeneity
governing GBM progression and resistance to therapy
[4–6]. Defects in several DNA repair mechanisms, espe-
cially in the repair of DNA double strand breaks (DSBs),
are known to enable genomic aberrations, such as
deletions and amplifications, in GBM [7, 8]. Despite the
extensive genomic analyses performed thus far, the GBM
genome may yet harbour additional etiological clues that
could improve treatment and patient outcomes.
L1 retrotransposons are endogenous mutagens known
to cause sporadic disease, including cancer [9]. A full-
length human L1 is ~6 kb long [10, 11] and contains a
5′ untranslated region (UTR), two non-overlapping open
reading frames that encode respectively for a 40KDa
* Correspondence: paul.brennan@ed.ac.uk; faulknergj@gmail.com
†Equal contributors
5Edinburgh Cancer Research Centre, IGMM, University of Edinburgh,
Edinburgh EH42XR, UK
1Mater Research Institute - University of Queensland, TRI Building,
Woolloongabba, QLD 4102, Australia
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Carreira et al. Mobile DNA  (2016) 7:21 
DOI 10.1186/s13100-016-0076-6
RNA binding protein (ORF1p) [12, 13] and a 150KDa
protein with both endonuclease (EN) and reverse tran-
scriptase (RT) activities (ORF2p) [14, 15], and a 3′UTR.
The L1 5′UTR bears an internal promoter with sense
and antisense activity [16, 17] and a recently described
antisense open reading frame (ORF0) [18]. Canonical L1
mobilisation depends on the transcription and transla-
tion of L1 and the formation of a ribonucleoprotein
particle (RNP) consisting of ORF1p and ORF2p, and
their encoding mRNA. Once the RNP enters the nu-
cleus, the L1-encoded EN can cleave genomic DNA [15]
and, typically, generate a new L1 insertion via target-
primed reverse transcription (TPRT) [19]. Hallmarks of
L1 integration by TPRT include use of an L1 EN recog-
nition motif (5′-TT/AAAA), target site duplications
(TSDs), and an L1 poly-A tail [20]. Endonuclease-
independent (ENi) L1 mobilisation can also occur into
pre-existing DNA double strand breaks, producing inser-
tions that lack TPRT hallmarks [21–24]. Notably, L1 can
mobilise other polyadenylated RNAs, such as Alu retro-
transposons, in trans [25–27]. L1 and Alu elements can
also participate in DNA rearrangements driven by re-
combination [28, 29]. Although TPRT-mediated L1 mo-
bilisation occurs in many cancers [30–38] and neural cells
[39–42], several recent studies employing high-throughput
sequencing have reported a surprising absence of somatic
L1 insertions in brain tumours [6, 30–32, 35].
We hypothesised that L1-associated DNA rearrange-
ments in GBM might occur via recombination or an
atypical retrotransposition mechanism and therefore
may lack the TPRT hallmarks required for L1 insertion
recognition by previous genomic analyses. Alternatively,
we considered that L1 insertions in GBM could be
restricted to sub-clonal and highly heterogeneous events.
We therefore applied deep retrotransposon capture
sequencing (RC-seq) [34, 42] to 14 brain tumour pa-
tients (9 GBM and 5 lower grade glioma) and detected
tumour-specific L1-associated mutations lacking TPRT
hallmarks in 4 GBM tumour samples, and also found no
examples of TPRT-driven L1 mobilisation. Complementary
assays using an engineered L1 reporter assay [43] revealed
negligible in vitro L1 activity in all tested GBM cell lines.
These experiments confirm that L1 mobilisation is absent
or very rare in GBM tumours and cell lines. Unusual
endonuclease-independent L1 retrotransposition or L1-
associated recombination events can however occasionally
occur, and may impact the expression of genes relevant to
GBM aetiology and neural cell morphology.
Methods
Patient samples
Tissues were obtained from 14 patients undergoing
surgical removal of a brain tumour at the Department of
Clinical Neurosciences, Western General Hospital,
Edinburgh, UK. All patients gave informed consent for
tumour and peri-tumoural tissue removed in the normal
course of surgery, and blood obtained intra-operatively, to
be used for research. Ethical approval for the study was
granted to P.M.B. by the East of Scotland Research Ethics
Service (SR018). Tissue designation as ‘tumour’ or ‘adja-
cent brain’ was determined at the time of sampling based
on pre-operative imaging, intra-operative image guidance
and macroscopic inspection. Blood was sampled from 9
patients (Additional file 1: Table S1) intra-operatively and
stored in lithium/heparin tubes. Tissue and blood samples
were snap frozen on dry ice within 30 min of sampling
and stored at −80 °C. Ethical approval for subsequent
experiments performed at the Mater Research Insti-
tute – University of Queensland was granted to G.J.F.
by the Mater Health Services Human Research Ethics
Committee (Reference: 1915A) and the University of
Queensland Human Research Ethics Committee (Reference:
2014000221). From all samples, genomic DNA was iso-
lated by standard phenol-chloroform extraction.
RC-seq libraries and sequencing
Paired-end 150mer multiplexed Illumina libraries were
constructed from genomic DNA samples as described
previously [34], with the following minor modifications:
sonicated DNA was size selected for fragments of 230–
260 bp by gel purification and used as template for 10 -
cycles of ligation-mediated PCR (LM-PCR). Libraries
were quantified and insert size confirmed using an
Agilent Bioanalyzer 2100 with a DNA1000 chip (Agilent
Technologies, USA). L1 enrichment was achieved via
two different RC-seq capture designs. Equimolar quan-
tities of tumour and adjacent brain libraries from
patients #1-#5 were pooled and hybridised to a second
generation (V2) RC-seq capture pool [34] composed of
80 biotinylated oligonucleotide probes tiled across the
L1-Ta consensus sequence L1.4 [44] 5′ and 3′ ends
(Additional file 2: Figure S1A). Hybridisation and library
processing were performed as described previously [34].
L1 enriched libraries were sequenced on Illumina
HiSeq2000 platform (BGI-Shenzhen, China).
Three additional library pools comprising i) tumour
and adjacent brain from patients #1-#7, ii) tumour and
adjacent brain from patients #8-#14 and iii) blood from
patients #6-#12 and #14 were hybridised using a third
generation (V3) RC-seq capture protocol involving only
two optimised, custom locked nucleic acid (LNA) oligo-
nucleotide probes (Exiqon Vedbaek, Denmark) respect-
ively targeting the 5′ and 3′ ends of L1.4 [42] (Fig. 1a).
LNA probe LNA-D/5Biosg/CTCCGGT + C + T +ACAG
CTC + C + C +AGC targeted the 5′ end and LNA-B/
5Biosg/AG +A + TGAC +A + C +ATTAGTGGGTGC +
A +GCG targeted the 3′ end (+ denotes LNA positions
within each probe). Pools i) and ii) were sequenced on
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an Illumina HiSeq2500 (Ambry Genetics, USA). Pool iii)
was sequenced by multiple Illumina MiSeq runs. A total
of 3,252,752,806 2x150mer RC-seq reads were generated
(Additional file 1: Table S1). RC-seq FASTQ files are
available from the European Nucleotide Archive (ENA)
under the identifier PRJEB1785.
RC-seq bioinformatic analysis
RC-seq read data were analysed using TEBreak (https://
github.com/adamewing/tebreak/tree/f7f01c1) with set-
tings –mincluster 2, −minclip 30, −minq 1. Briefly,
TEBreak aligned RC-seq reads against the human refer-
ence genome (hg19) using BWA-MEM [45] with set-
tings –Y and –M to output soft-clipped secondary
alignments. PCR duplicates were marked with MarkDu-
plicates from the Picard Tools library (http://broadinsti-
tute.github.io/picard/). Non-duplicate reads that aligned
partially to the reference genome but had ≥30 nt soft-
clipped from either end were retained; clipped ends were
then aligned against L1.4 using the same BWA-MEM
settings. Split-read mappings joining an L1 to the refer-
ence genome were then clustered and annotated for the
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Fig. 1 Characterisation of a somatic L1-associated DNA rearrangement within MeCP2. a Patient #2 MeCP2 mutant allele: a 0.9 kb L1PA2
sequence antisense to MeCP2. Direction of transcription (blue arrows), transcript isoforms (purple/pink lines) and qRT-PCR primers for MeCP2
expression assays (arrowheads) are indicated. b L1 mutation magnified view: RC-seq reads detected at the L1 5′ terminus (black/white bars). The L1
sequence comprises a truncated fragment of L1 ORF2 (white box), the 3′UTR without a poly-A tail (red box) and 37 nt from an Alu (black box). A 58
nucleotide deletion was also identified (triangle). Primers used for PCR validation are indicated as grey arrows. c Mutation site PCR validation: the
mutant MeCP2 allele carrying L1 (filled) was only detected in patient #2 tumour whilst the empty site was found in both tumour and adjacent brain
samples. No amplification was detected when water was used as template (NTC). d qRT-PCR measurement of MeCP2 transcript isoforms: The relative
levels of RNA from both isoforms were significantly reduced in tumour (blue) versus adjacent brain (green) samples. Data for each group were
normalised to non-tumour values, pooled and presented as mean +/− SEM (*p < 0.008, two tailed t-test, df = 6). Text colour relates with the primer pair
used as represented in (a). e qRT-PCR measurement of L1 transcript abundance measured at the L1 5′UTR and ORF2 regions: The relative levels of RNA
from both regions were significantly increased in tumour (blue) versus adjacent brain (green) samples. Data for each group were normalised to adjacent
brain values, pooled and presented as mean +/− SEM (*p < 0.001, two tailed t-test, df = 10). f L1 promoter methylation: CpG methylation was measured
across the L1 promoter CpG-island sequence. Tumour samples (blue) showed reduced methylation when compared to adjacent brain samples (green).
Data for each group were normalised to non-tumour values, pooled and presented as mean +/− SEM (*p < 0.001, paired t-test, df = 18)
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presence of TSDs or deletions. Clusters with at least two
reads supporting a consistent breakpoint were output in
VCF format and further post-processed using the sum-
mary.py script included in the TEBreak distribution.
This further filtered candidates by ensuring a consistent
breakpoint between BWA-MEM and BLAT [46] align-
ments, excluded clusters mapping to locations in the ref-
erence genome occupied by other L1s and required that
the consensus sequence of each cluster matched L1.4 by
at least 90 % over ≥30 nt and the reference genome by at
least 95 % based on the BLAT alignment.
RC-seq sensitivity for each library was assessed based
on a cohort [41] of 960 reference genome L1-Ta and L1
pre-Ta insertions with intact 3′ ends (Evrony et al. Table
S5, “Category 4”) detected by ≥20 and ≥8 reads for pa-
tients #1-#5 and #6-#14, respectively (Additional file 1:
Table S1). Sensitivity was further assessed in terms of
polymorphic L1 insertions detected in each individual,
with ≥10 and ≥4 reads required in both the tumour and
other (adjacent brain and blood) libraries for patients
#1-#5 and #6-#14, respectively, to report an L1 insertion
(Additional file 1: Table S1). These thresholds exceed
those used in another recent work, where we reported a
98.5 % validation rate for polymorphic L1 insertions de-
tected by 2 RC-seq reads and tested by PCR [34]. RC-
seq coverage statistics presented in Additional file 1:
Table S1 were calculated as the total number of RC-seq
reads in a given library that spanned a 5′ or 3′ L1-
genome junction of the abovementioned cohort of 960
reference genome L1 insertions, divided by 960 to gener-
ate an average value. Non-reference L1 insertions were
annotated as tumour-specific if they were: i) found in
only one tumour sample with ≥8 RC-seq reads and
>10× more RC-seq reads than all other samples com-
bined, ii) absent from published L1 polymorphism
databases [30, 32–35, 47–51], iii) likely to be found
by the corresponding RC-seq capture design (a 5′ L1-
genome junction for an L1 > 6000 nt, <1000 nt in
length or a 3′ L1-genome junction), iv) with TEBreak
‘strand confidence’, ‘family confidence’ and ‘position
confidence’ scores of >0.9, >0.9 and >0.3, respectively, and
v) presented microhomology of <10 nt between the inte-
gration site and L1.4 (to exclude possible molecular chi-
meras). Four putative tumour-specific L1 mutations were
reported at these thresholds (Additional file 1: Table S2).
L1 mutation PCR validation
Empty/filled site PCR assays were used to validate
tumour-specific L1 mutations detected by RC-seq.
Primers flanking either side of each insertion were de-
signed using Primer3 [52] (Additional file 1: Table S3).
PCR reactions involved the following reagents: 1U
MyTaq DNA polymerase (Bioline, Australia, #BIO-
21106), 1× MyTaq Reaction Buffer, 2 μM primers and
20 ng template DNA in a 25 μL reaction volume with
the following cycling conditions for the MeCP2 L1 mu-
tation: 3 min at 92 °C, then 10 cycles of 30s at 92 °C, 30s
at 60 °C and 6 min 30s at 68 °C, followed by 20 cycles of
30s at 92 °C, 30s at 58 °C and 6 min 30s at 68 °C (in-
creasing by 20s per cycle), followed by a single extension
step at 68 °C for 10 min. Products were treated with
ExoSap-IT (Affymetrix, USA), with 2 μL of product then
used for a second PCR reaction with the same condi-
tions as the first round, except with 30 cycles in the
second phase. For the EGFR L1 mutation, PCR was
performed using primers targeting the 5′ L1-genome
junction with the following cycling conditions: 2 min at
95 °C, then 20 cycles of 15 s at 95 °C, 30s at 59 °C and
30s at 72 °C, followed by a single extension step at 72 °C
for 10 min. Products were again treated with ExoSap-IT,
with 2 μL of product used for a second PCR reaction
with the same conditions as the first round, except with
30 cycles. PCR products were capillary sequenced using
an ABI3730 (AGRF, Brisbane, AUS) and the results are
provided in Additional file 1: Table S3.
qRT-PCR analyses
Snap frozen tumour and adjacent brain tissues from patient
#2 were shaved with a scalpel on dry ice and re-suspended
in Trizol Reagent (Invitrogen, Life Technologies, USA,
#15596-026) following manufacturer’s instructions for total
RNA isolation. Quantification was performed using Nano-
Drop 1000 (Thermo Fisher Scientific, USA). 2 μg total
RNA was treated with DNase I (Ambion, Life Technolo-
gies, USA, #AM1906) and used as template for cDNA
synthesis with SuperScript III Reverse Transcriptase (Invi-
trogen, Life Technologies, USA, #18080-093) following
manufacturer’s instructions. 2 μg total RNA was processed
as described with no reverse transcriptase added to the
cDNA synthesis reaction for further use as negative control
(RT-). cDNA from adjacent brain tissue was diluted to final
concentrations of 1:5, 1:10, 1:20, 1:40 and 1:80 and used to
generate a standard curve for each primer set. Samples
were diluted to 1:20 final concentration for qRT-PCR. Real
time PCRs were performed using SensiFast SYBR Lo-ROX
kit (Bioline, Australia, #BIO-94005) and run on a ViiA 7
Real-Time PCR System (Life Technologies, USA) with
standard curve experiment analysis settings. Negative con-
trol qRT-PCRs were performed using water as template (no
template control, NTC) and 2 μl of RT- reaction; no ampli-
fication was detected. MeCP2 isoforms (NM_004992) were
assessed using 5′-GAGGCGAGGAGGAGAGAC and 5′-
TGGTAGCTGGGATGTTAGGG as forward primers for
isoforms 1 and 2, respectively, and 5′-GCAGAGTGGT
GGGCTGAT as a common reverse primer to amplify
154 nt of isoform 1 and 161 nt of isoform 2. Additionally,
143 nt of the MeCP2 exon 4, present in both isoforms,
were amplified using 5′-CAGAGGAGGCTCACTGGAGA
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as forward primer and 5′-GGCATGGAGGATGAA
ACAAT as reverse primer. EGFR (NM_005228) was ampli-
fied on the 5′UTR (amplicon of 156 nt) and the junction
between exons 11 and 12 (176 nt) with the following
primers:
EGFR 5′UTR, 5′-CCAGTATTGATCGGGAGAGC
C, 5′-CTCGTGCCTTGGCAAACTTTC
EGFR exon 11–12 junction, 5′-GACCAAGCAACAT
GGTCAGT, 5′-TTTTCTGACCGGAGGTCCCA
L1 (L1.4) expression was assessed by targeting 61 nt of
the 5′UTR and 85 nt of the ORF2 with the primers: L1
5′UTR:
5′-ACAGCTTTGAAGAGAGCAGTGGTT, 5′-AG
TCTGCCCGTTCTCAGATCT
L1 ORF2: 5′-TGCGGAGAAATAGGAACACTTTT,
5′-TGAGGAATCGCCACACTGACT
156nt of TATA-binding protein mRNA (TBP,
NM_003194) and 173 nt of beta actin mRNA (ACTB,
NM_001101) were amplified with the following primers:
TBP, 5′-GCAAGGGTTTCTGGTTTGCC, 5′-GGG
TCAGTCCAGTGCCATAA
ACTB, 5′-AGAAAATCTGGCACCACACC, 5′-TA
GCACAGCCTGGATAGCAA
Standard curve parameters for qRT-PCR (slope, y-
intercept, r2) are as follows: MeCP2 isoform 1: −3.312,
29.329, 0.95; MeCP2 isoform 2: −2.946, 29.578, 0.943;
MeCP2 exon 4: −3.796, 27.991, 0.897; EGFR 5′UTR:
−4.057, 30.028, 0.931; EGFR exon 11–12 junction:
−4.660, 28.317, 0.985; TBP: −3.754, 27.208, 0.973; L1 5′
UTR: −3.094, 21.209, 0.996; L1 ORF2: −3.11, 18.836,
0.9992; ACTB: −3.954, 22.606, 0.999.
Relative expression levels were calculated using five
technical replicates and normalised to TBP (for MeCP2
and EGFR) or ACTB (for L1). Statistical analysis was
performed with Prism5 (GraphPad Software), applying a
t-test with a 99 % confidence interval.
cDNA from patient #2 tumour was used as template
for RT-PCR to amplify possible L1-MeCP2 chimeric
transcripts. The following chimeric variants were tested;
Exon 1–L1, using a forward primer within exon 1 5′-
GAGGCGAGGAGGAGAGAC and a reverse primer
within the new L1, 5′-CACCAGCATGGCACATGTAT.
Exon 2–L1, forward primer (5′-TGGTAGCTGGGAT
GTTAGGG) in exon 2 and reverse primer within L1
(5′-CACCAGCATGGCACATGTAT). L1-Exon 3, with
the L1 primer as a reverse primer (5′-GCACATTGTGC
AGGTTAGTTAC) and a forward primer within exon 3,
(5′-GCAGAGTGGTGGGCTGAT).
MeCP2 deletion quantification
5 ng of genomic DNA from patient #2 adjacent brain
and tumour were used as a template for a PCR to amp-
lify the deleted region within MeCp2 using 5′-AAATTA
GCCAGGCGTGGTG as forward primer within the de-
leted region and 5′-TCCTGTTTTGTCTTACGTCTTG
A as reverse primer downstream of the deleted region.
The PCR conditions were as follow; 1U MyTaq DNA
polymerase (Bioline, Australia, #BIO-21106), 1× MyTaq
Reaction Buffer, 2 μM primers and 5 ng template DNA
in a 25 μL reaction volume with the following cycling condi-
tions: 3 min at 92 °C, then 35 cycles of 15 s at 92 °C, 15 s at
56 °C and 15 s at 72 °C, followed by a single extension step
at 72 °C for 10 min. PCR amplicons were resolved in a 2 %
agarose gel and scanned (Typhoon FLA 9500, GE Health-
care life science, US). Amplicons present on the scanned
picture was quantified using Image Studio Lite version 4
software (LI-COR Biosciences). Values were corrected for
background and normalised to adjacent brain value.
L1 promoter methylation
200 ng of genomic DNA extracted from tumour and adja-
cent brain tissues was bisulfite converted using EZ DNA
Methylation-Lightning Kit (Zymo Research, CA, USA)
following manufacturer’s instructions. After purification,
2 μL was used as template for a PCR reaction using L1-
Bis-F and L1-Bis-R primers as described by Shukla et al.
[34]. PCR reactions were performed using MyTaq DNA
polymerase (Bioline, Australia, #BIO-21106) in a 25 μL
volume with the following cycling conditions: 2 min at
95 °C, then 25 cycles of 15 s at 95 °C, 60s at 55 °C and 60s
at 72 °C, followed by a single extension step at 72 °C for
10 min. The ~350 bp PCR product was gel purified using
QIAquick gel extraction kit (QIAGEN, NLD). Illumina li-
braries were generated for each purified PCR product
using the NEBNext Ultra DNA Library Prep Kit (New
England Biolabs Inc., USA) following manufacturer’s in-
structions and sequenced on an Illumina MiSeq. 250mer
paired-end reads were assembled into single contigs using
FLASH [53] (−m 15 -M 150 -× 0.3). Contigs were
then aligned to the mock bisulfite converted L1-Ta
consensus L1.4 using blastn (−dust no -penalty −1 -gapopen
2 -gapextend 1 -max_target_seqs 1). The methylation status
of CpG sites in the L1.4 promoter CpG island was used to
compare tumour and adjacent brain L1 promoter methyla-
tion, as performed previously [34]. Mutated CpG dinucleo-
tides were excluded from analysis, as were reads with less
than 95 % conversion of non-CpG cytosines.
Patient #2 and #8 whole genome sequencing and analysis
Illumina libraries (TruSeq Nano DNA sample prepar-
ation kit) were generated from patient #2 tumour and
adjacent brain and, for patient #8, tumour and blood
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genomic DNA. Libraries had an insert size of ~300 nt
and were sequenced on an Illumina HiSeq X Ten plat-
form (Kinghorn Centre for Clinical Genomics, Garvan
Institute of Medical Research, Australia). Reads were
aligned to hg19 using BWA-MEM (parameters –Y –M
–R < read group name>) and sorted using SAMtools
[45]. PCR duplicates were marked using MarkDuplicates
and local INDEL realignment was carried out with
GATK 3.3. Patient #2 adjacent brain and tumour librar-
ies were sequenced to 44.3× and 84.6×, respectively.
Patient #8 blood and tumour libraries were sequenced to
59.8× and 124.2× aligned read depth, respectively. Point
mutations and short insertions/deletions were detected
using Strelka [54] and Platypus [55]. Structural rear-
rangements were detected using Delly [56] and Manta
[57] and somatic CNVs were detected using cn.MOPS
[58], cross-referenced with SV calls, and manually
inspected (Additional file 3: Figure S3, Additional file 4:
Figure S4, Additional file 5: Figure S5 and Additional
file 6: Figure S6). WGS FASTQ files are also available
from the ENA under the identifier PRJEB1785.
Cell culture
GBM cell lines were purchased from American Type
Culture Collection (ATCC, USA) and grown in a hu-
midified, 5 % CO2 incubator at 37 °C in the complete
media as described by the provider. DBTRG-05MG
(ATCC, USA, #CRL-2020) cells were grown in ATCC-
formulated RMPI-1640 medium (Gibco, Life Technolo-
gies, USA, #A10491-01) supplemented with 10 % foetal
bovine calf serum (Gibco, Life Technologies, USA,
#16000044), non-essential amino acids (Gibco, Life
Technologies, USA, #11140050) and 100 U/mL penicil-
lin, 0.1 mg/mL streptomycin (Gibco, Life Technologies,
USA, #15140122) to generate complete media. M059J
(ATCC, USA, #CRL-2366) cells were grown in media
containing a 1:1 mixture of Dulbecco’s Modified Eagle’s
Medium and Ham’s F12 Medium (DMEM-F12, ATCC,
USA, #30-2006) supplemented with 10 % foetal bovine
calf serum, non-essential amino acids and 100 U/mL
penicillin, 0.1 mg/mL streptomycin. LN18 (ATCC, USA,
#CRL-2610) and LN229 (ATCC, USA, #CRL-2611) were
grown in Dulbecco’s Modified Eagle’s Medium (DMEM,
ATCC, USA, #30-2002) supplemented with 5 % foetal
bovine calf serum and 100 U/mL penicillin, 0.1 mg/mL
streptomycin. HeLa cells were grown in a humidified, 5 %
CO2 incubator at 37 °C in the complete media, Dulbecco’s
Modified Eagle’s Medium (DMEM, ATCC, USA, #30-
2002) supplemented with 10 % foetal bovine calf serum
and 100 U/mL penicillin, 0.1 mg/mL streptomycin.
Generation of L1 retrotransposition assay plasmids
Plasmids carrying i) an L1 EN mutant (pCEP4-
L1.3D205A) [23] and ii) an L1 reverse transcriptase
mutant (JJ105-L1.3-D702A) [59, 60] were digested with
NotI-Hf and BstZ17I restriction enzymes (New England
Biolabs, USA, #R3189 and #R0594) at 37 °C for 2 h to
obtain L1.3-D205A and the JJ-NotI-Hf/BstZ17I back-
bone. This backbone was also treated with alkaline phos-
phatase (New England Biolabs, USA, #M0290) for
30 min at 37 °C to use for subsequent cloning. Purified
L1.3-D205A was ligated to the JJ-NotI-Hf/BstZ17I back-
bone using T4 ligase (New England Biolabs, USA,
#M0202) for 2 h at room temperature generating JJ-
L1.3-D205A. To obtain wild-type L1.3 (L1.3 WT) [61]
and L1.3-D205A/D702A (EN and RT double mutant)
constructs, plasmids carrying the individual mutations
were digested with EcoRI (New England Biolabs USA,
#R3101), NotI and BstZ17I simultaneously (2 h at 37 °C).
Fragments corresponding to L1.3-NotI/EcoRI, L1.3-D205A-
NotI/EcoRI, L1.3-EcoRI/BstZ17I and L1.3-D702A-EcoRI/
BstZ17I were gel purified. L1.3-NotI/EcoRI and L1.3-EcoRI/
BstZ17I were ligated to JJ-NotI-Hf/BstZ17I backbone to ob-
tain JJ-L1.3 plasmid. JJ-L1.3-D205A-D702A was generated
by ligation of L1.3-D205A-NotI/EcoRI and L1.3-D702A-
EcoRI/BstZ17I to the JJ-NotI-Hf/BstZ17I backbone. Liga-
tions were transformed in One Shot TOP10 Chemically
Competent E. coli bacteria (Invitrogen, Life Technologies,
USA, #C4040), and plated in LB-agar (Sigma-Aldrich, USA,
#L2897) and 100 μg/ml ampicillin (Sigma-Aldrich, USA,
#A9518). All plasmid sequences were confirmed by capil-
lary sequencing.
L1 retrotransposition assay
Plasmid DNA was purified on maxiprep columns
(Qiagen, NED, #12143) and diluted in sterile dH2O to
0.5 μg/μL. GBM cells were seeded in 6-well dishes in
their respective complete media to ~25 % confluence.
Cells were transfected at the time of seeding with
FuGENE HD transfection reagent (Promega, USA,
#E2312) following the manufacturer’s protocol using 1:4
DNA: FuGENE ratio. Each transfection well received
1 μg plasmid DNA, 4 μL FuGENE reagent and 2 mL of
complete media. Media was changed 24 h post transfec-
tion and selection with blasticidin S HCl (Life technolo-
gies, USA, #A11139) began 4 days post transfection.
Cells were selected for antibiotic resistance for 10 days
using a final concentration of 5 μg/ml for HeLa,
DBTRG-05MG and LN229 and 2 μg/mL for LN18 and
M059J.13-14 days post transfection, cells were washed
twice with 1xPBS and fixed and stained as described by
Moran et al. [43].
Transfection efficiency for each plasmid was calculated
by flow cytometry (BD FACSCanto II, BD Bioscience,
USA). GBM cell lines were co-transfected as described
above with 0.5 μg of each JJ construct and 0.5 μg of
pCAG-GFP (plasmid that constitutively expresses GFP).
72 h post-transfection, cells were harvested and re-
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suspended in 1× PBS. Propidium iodide (Thermo Fisher,
Life Technologies, USA, #P3566) was added to the sam-
ples for identification of dead cells. GFP positive cells
were gated based on fluorescence of untransfected cells
and transfection efficiency calculated as the percentage
of GFP positive cells using FlowJo 10.0.8 software
(FlowJo LLc., USA) (Additional file 7: Figure S2,
Additional file 1: Table S4).
Results
L1 mutations identified in 4 GBM tumours
We applied RC-seq to 9 GBM and 5 lower grade glioma
sample sets, including tumour and matched adjacent
brain or blood (Additional file 2: Figure S1A, Additional
file 1: Table S1). Tumour and non-tumour samples from
five of these patients were sequenced to ~250× coverage
of targeted L1-genome junctions by RC-seq, while sam-
ples from the remaining individuals were sequenced to
~55× coverage. Overall, we detected 93.6 % of 960
reference genome copies [41] of the most active human
L1 subfamily, L1-Ta, as well as an average of 208 poly-
morphic L1-Ta insertions per sample (Additional file 1:
Table S1), despite stringent RC-seq reporting thresholds
(see Materials and Methods).
We identified four putative tumour-specific L1 muta-
tions in four different GBM patients (Additional file 1:
Table S2). Three of these mutations were located within
genes known to be active in the brain (MeCP2, EGFR
and CEP112) while the other was intergenic and was not
associated with a known regulatory element, such as a
promoter region or annotated enhancer (Additional file
1: Table S2). The putative tumour-specific L1 mutations
in MeCP2 and EGFR were validated via PCR (see below).
The remaining two events identified by RC-seq could
not be confirmed by PCR and hence their structures
could not be fully elucidated. RC-seq read information
however indicated that the putative L1 insertion in
CEP112 involved an L1-Ta donor sequence, a long
(102 nt) poly-A tail and a degenerate L1 EN recognition
motif, suggesting potential TPRT-mediated L1 mobilisa-
tion, albeit without corroboration via PCR. The remaining
putative L1 mutation was annotated as an older L1PA2
element, which are usually not capable of autonomous ret-
rotransposition in humans [62], and also lacked an L1 EN
motif. These features are consistent with a DNA re-
arrangement rather than a retrotransposition event. No
somatic L1 sequence variants were detected in lower
grade glioma samples.
Structure and impact of a de novo L1-associated DNA
rearrangement within MeCP2
In patient #2, a female, we identified a putative intronic
L1 mutation in the methyl CpG binding protein 2
(MeCP2) gene by RC-seq that was confirmed by PCR
(Fig. 1a-c, Additional file 2: Figure S1B-C, Additional file
1: Table S2). MeCP2 is an X-chromosome linked tran-
scription factor necessary for neural differentiation and
is defective in the neurodevelopmental disorder Rett
syndrome [63]. MeCP2 binds and generally represses
methylated DNA genome-wide, including the CpG-
island present in the canonical L1 5′ promoter [64]. Se-
quence characterisation revealed that the L1 sequence
belonged to the L1PA2 subfamily, was 5′ truncated and
carried a 49 nt 3′ flanking region from its L1 donor
element on chromosome 9. The L1 mutation site lacked
an L1 EN recognition motif and TSDs, and incorporated
a 58 nt genomic deletion (Fig. 1b, Additional file 2:
Figure S1B), features strongly inconsistent with retro-
transposition through TPRT. Further analysis revealed
that the 3′ flanking region carried with the L1 com-
prised an Alu retrotransposon and that integration oc-
curred into another Alu element. These features led us
to conclude that this L1-associated event was probably
driven by recombination of the Alu adjacent to the
L1PA2 donor sequence with the Alu present in MeCP2.
Quantitative RT-PCR revealed significant (p < 0.008, t-
test) reductions in tumoural expression of both of the
two main MeCP2 transcript isoforms (Fig. 1a, d). Using
additional primers specific to the L1 mutation, we per-
formed qRT-PCR to evaluate whether the L1 generated
a chimeric transcript with upstream or downstream
MeCP2 exons. However, chimeric L1-MeCP2 RNA spe-
cies were not detected by this assay (data not shown).
WGS applied to patient #2 tumour and adjacent brain
revealed tumour-specific copy number gain at the
MeCP2 locus and an absence of single nucleotide vari-
ants or DNA rearrangements, other than the L1 muta-
tion. Quantitative PCR measuring copy number of the
genomic region deleted 3′ of the L1 mutation confirmed
that the L1-mutant MeCP2 allele was amplified in the
tumour as, despite overall amplification of the MeCP2
locus as detected by WGS, we identified copy number
loss of this deleted 3′ sequence in the tumour. MeCP2 is
known to regulate L1 activity by binding the methylated
CpG-island present in the canonical L1 5′ promoter
[64]. Therefore, as an evidence of a reduction in MeCP2
activity, we detected significantly higher (p < 0.0001, t-
test) L1 mRNA abundance in patient #2 tumour versus
adjacent brain (Fig. 1e), as well as significant tumour-
restricted hypomethylation of the canonical L1-Ta
promoter (p < 0.0001, t-test) (Fig. 1f ). Replicate PCR per-
formed on seven spatially disparate tumour foci detected
the L1 mutation in all locations (Additional file 2: Figure
S1C). These data suggest that the MeCP2 L1 mutation
underwent copy number gain, was present in clonally
amplified cells, and may have impacted MeCP2 expres-
sion and function throughout the tumour mass. Given
these results, we propose transcriptional disruption by
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the L1 [65] as a plausible cause for reduced MeCP2 ex-
pression, although we cannot rule out the involvement
of another mechanism.
Structure of a tumour-specific L1 mutation within EGFR
In patient #8, RC-seq detected a putative tumour-
specific L1 mutation in the first intron of the epidermal
growth factor receptor gene (EGFR) (Fig. 2a), a major
oncogene amplified or otherwise altered in >60 % of
GBM cases [6]. PCR validation and capillary sequencing
showed a 5′ truncated L1 sequence of the L1-Ta sub-
family and lacking a 3′ poly-A tail and TSDs, and here
incorporating a 550 nt genomic deletion (Fig. 2b-c,
Additional file 2: Figure S1D). Although these features
are consistent with ENi L1 retrotransposition, we cannot
fully exclude the possibility that this event arose via L1-
associated DNA recombination. PCR upon multiple
tumour foci suggested that the L1 mutation was clonally
amplified (Additional file 2: Figure S1E). Unlike the
MeCP2 L1 mutation, the EGFR L1 mutation did not ap-
pear to impact host gene expression. Indeed, EGFR ex-
pression was significantly up-regulated in patient #8
tumour versus adjacent brain tissue (p < 0.0001, t-test)
(Fig. 2d). As EGFR structural and copy number variation
is a common feature of GBM [6], we performed WGS
on patient #8 tumour and blood samples, elucidating
major (>50×) copy number amplification of EGFR and
the surrounding genomic locus (Fig. 2e). Given the
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extreme copy number gain and the presence of discord-
ant read pairs supporting a junction between the 5′ and
3′ ends of the amplified genomic segment, this event
was likely to represent a double minute chromosome
[66] containing EGFR. Further WGS data analysis sug-
gested that the majority of additional EGFR alleles did
not incorporate the L1 mutation, indicating that copy
number amplification primarily drove EGFR induction.
Whole genome analysis of patients #2 and #8
To place the PCR validated L1-associated mutations in
MeCP2 and EGFR into a broader context of genomic ab-
normality, we analysed WGS data from patients #2 and #8
(Additional file 1: Table S5). For patient #2, we compared
tumour tissue and adjacent tissue that appeared patho-
logically normal. Here we found that a significant portion
of cells from the normal tissue did in fact contain tumour
cells based on the presence of mutations at low variant
allele fraction (VAF) in the normal tissue and at an in-
creased VAF in the tumour tissue. For example, we identi-
fied a TP53 mutation (c.421C > T/p.Arg141Cys) present in
18.5 % of sequencing reads from adjacent tissue and
90.9 % of tumour reads. This mutation corresponded to
rs121913343/COSM3719990 (dbSNP/COSMIC) but may
have been somatic in this instance given the low VAF in
normal tissue. Other potentially pathogenic point muta-
tions in patient #2 included an established GBM mutation
in the IDH1 gene at p.Arg132His [6]. We observe LOH
over APC leading to at least two non-synonymous
changes increasing in VAF to >95 % (rs139196838,
rs459552). The tumour from patient #2 presented variable
5–10 fold amplification across 4q12 (Additional file 3:
Figure S3A), which included the tyrosine kinase KIT, and
tyrosine kinase receptors PDGFRA and KDR (VEGFR2)
(Additional file 3: Figure S3B). Amplifications of this re-
gion occur frequently in GBM [67]. We also detected a
focal ~2.7kbp deletion removing both copies of CDKN2A
exon 2 inside of a larger single-copy region encompassing
CDKN2A/B (Additional file 4: Figure S4). Finally, we de-
tected copy number amplifications at the end of the q arm
on chromosome X, which indicated one additional copy
in two regions, one of which included MeCP2 (Additional
file 5: Figure S5). This copy number increase provides a
reasonable explanation for the 50 % decrease in MeCP2
expression in this tumour relative to the adjacent tissue,
due to the aforementioned intronic L1 mutation in the
amplified MeCP2 allele (Fig. 1).
As noted above, the tumour sample from patient #8
showed a remarkable amplification of EGFR (>50 fold,
Fig. 2e, Additional file 6: Figure S6A), likely due to a
double minute chromosome as observed in many other
GBM cases [66]. Additionally this tumour contained a
deletion surrounding CDKN2A/B, and an amplification
of the RAS-related oncogene RAB14 on chr9q33.2
(Additional file 6: Figure S6B). There were few point
mutations affecting known cancer or GBM-associated
genes detected in this sample at appreciable (>10 %)
VAF. The detected examples include a frameshift muta-
tion of the histone methyltransferase and known tumour
suppressor SETD2 (p.Asp14fs) that can activate TP53
and is necessary for DSB repair via homologous recom-
bination [68, 69], and a putative splice donor site muta-
tion affecting CIITA (class II MHC transactivator).
Thus, the L1 mutation observed here in EGFR was likely
a passenger to the main oncogenic transformation enab-
ling tumorigenesis in patient #8 and occurred in an
environment of impinged DNA repair.
GBM cell lines rarely support L1 retrotransposition
To assess whether GBM cell lines support canonical or
ENi L1 retrotransposition in vitro we performed an
established cultured cell retrotransposition assay [43] on
HeLa cells and four GBM cell lines (DBTRG-05MG,
M059J, LN 18 and LN 229). This assay relies on the ex-
pression of a blasticidin resistance gene carried by an L1
reporter construct, where blasticidin is only expressed
and confers resistance after L1 retrotransposition
(Fig. 3a). Each cell line was transfected in triplicate with
a set of 4 plasmids bearing different L1 sequences up-
stream of the antisense orientated blasticidin-resistance
gene [60] (Fig. 3b); a wild type full-length L1 (JJ L1.3
WT) [61], an L1 with an EN domain missense mutation
that abolishes L1 ORF2p EN activity (JJ L1.3 D205A)
[23], an RT mutated L1 with no reverse-transcriptase ac-
tivity (JJ L1.3 D702A) [59] and a double mutant L1 bear-
ing both EN and reverse-transcriptase mutations (JJ L1.3
D205A D702A). No L1 retrotransposition events were
detected for DBTRG-05MG, M059J or LN18 cell lines
and very few events (<4 events per well) were detected
for the L1.3 WT construct in LN 229 cells (Fig. 3c).
Mobilisation of the RT mutant and double mutant L1
reporter was not observed in any of the GBM cell lines.
By contrast, the positive control HeLa cells supported
the expected “hot” L1.3 WT activity [43, 70, 71] as well
as mobilisation of each L1.3 mutant to lesser extents.
These data indicate that GBM cell lines typically only
support very low or negligible L1 retrotransposition, in
line with our RC-seq data obtained from patient
tumour samples.
Discussion
These experiments reveal rare L1-associated mutations
caused by recombination or L1 ENi retrotransposition in
GBM tumours, accompanied by an absence of TPRT-
driven L1 insertions. Endonuclease-independent L1 in-
sertions have been reported by several prior studies
employing engineered L1 reporter constructs in cultured
cancer cells or cells otherwise deficient for DNA damage
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repair factors [21–23, 72, 73], or through bioinformatic
analysis of the human reference genome [24]. Unusual
L1 integration sites identified by these studies incorpo-
rated, amongst other features, genomic deletions, dele-
tions of the L1 3′ end and poly-A tail, absence of TSDs
and absence of an L1 EN recognition motif. Here, by
fully resolving the structures of GBM tumour-specific L1
mutations through RC-seq and capillary sequencing, we
confirmed they lacked a recognisable L1 poly-A tail or
TSDs, and incorporated genomic deletions. In the case
of the EGFR L1 mutation, these features are suggestive
of L1 ENi mobilisation, as primarily reported by others
using engineered L1 systems in vitro [21–23, 72, 73] or,
potentially, DNA recombination. Genomic abnormality
at L1 mutation sites may also explain failure to PCR val-
idate 2/4 observed putative tumour-specific L1
mutations. Notably, our WGS analyses elucidated muta-
tions in key DSB repair factors, such as SETD2 in pa-
tient #8, as well as TP53 deficiency in patient #2. Thus,
rare tumour-specific L1-associated mutations occur in
GBM in a milieu of deficient DSB repair previously en-
countered for similar events in vitro [21, 23].
Although identified at first by RC-seq as a potential L1
mobilisation event, further characterisation of the
MeCP2 L1 mutation indicated a probable DNA re-
arrangement event mediated by Alu:Alu recombination.
Notably, the Alu-flanked L1PA2 donor sequence, located
on chromosome 9, was 5′ truncated and did not encode
a viable L1 ORF2p. The involvement of an older L1 fam-
ily in a tumour-specific DNA rearrangement event is
reminiscent of one of the earliest L1 mutations detected
in cancer, in that case affecting the myc locus in breast
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tumour [74]. A lesser possibility is that the L1PA2 trans-
duced its flanking 3′ Alu during ENi L1 mobilisation in
trans, in agreement with a previous observation where
71 % of detected ENi L1 mobilisation events involved
non-L1 DNA [24], and involved single strand annealing
[72, 73, 75]. The tumour-specific L1 mutation in MeCP2
appeared to reduce the expression of this gene concomi-
tant with copy number gain for the L1 mutant MeCP2
allele and, as suggested by increased L1 expression and
reduced L1 5′UTR methylation, may have reduced
MeCP2 function throughout the tumour mass, causing a
molecular phenotype.
Notably, the EGFR L1 mutation provides an interest-
ing example because, despite not having a direct effect
on gene activity, it is one of very few tumour-specific L1
mutations noted in a major oncogene or tumour sup-
pressor since the first such example was discovered
more than 20 years ago by Miki et al. [9].
Previous studies employing high-throughput sequen-
cing reported no tumour-specific L1 insertions in brain
tumours [30–32, 35]. Iskow et al. did observe putative
tumour-specific L1 insertions, though subsequent PCR
validation experiments were unsuccessful [30]. Thus, al-
though the atypical L1-associated mutations reported
here represent the first PCR validated variants of this
type in in GBM, our in vivo and in vitro results agree
with prior reports of a lack of TPRT-driven L1 insertions
in brain cancers (Table 1). At the same time, the absence
of de novo L1 insertions in this context is intriguing,
given frequent somatic L1 mobilisation via TPRT in
neural cells [39–42], including glia [42]. To speculate,
one explanation for consistently limited L1 activity in
GBM could be that the relevant tumour initiating cells
only support L1 retrotransposition in the context of a
deficient DSB repair, perhaps due to the presence of L1
inhibiting host factors, including those affecting subcel-
lular localisation of the L1 RNP [76]. This conclusion
would disagree with GBM typically arising from de-
differentiated neural cells. Still, given the high RC-seq
coverage employed here, and evidence obtained using
the L1 reporter system in vitro, we consider this ex-
planation more appealing than tumoural heterogeneity
obscuring TPRT-driven L1 mobilisation.
Conclusions
Although we conclusively find that L1 mobilisation is a
rare event in GBM, our discovery of atypical L1-
associated mutations in MeCP2 and EGFR demonstrates
that L1 can otherwise contribute to GBM genome
abnormality in key loci regulating neural cell differenti-
ation and proliferation. Future experiments are required
to ascertain whether this phenomena correlates with
patient prognosis and whether potential DNA damage
caused by chemotherapy or radiotherapy [77] activates
L1 in recurrent GBM.
Additional files
Additional file 1: Table S1. RC-seq output summary. Table S2.
Polymorphic and somatic L1 mutations called by TEBreak. Table S3. List
of somatic L1 mutations and PCR validation information. Table S4. GBM
cell line transfection efficiencies. Table S5. Summary of point mutations
and CNVs detected from WGS (XLSX 335 kb)
Additional file 2: Figure S1. Structure and detection of L1 mutations
in MeCP2 and EGFR. (a) RC-seq versions: Capture probes from version 2
(V2, marked in blue) correspond to two sets of DNA oligonucleotides
mapping within the 5'UTR and the 3'UTR of the L1 sequence (UTRs
represented as red boxes). Version 3 (V3, marked in green) includes a
single LNA probe for each UTR. The 5' end probes capture only the 5'
junction of full or nearly full length insertions. The 3' end probes capture
both 3' junctions of insertions of all lengths and 5' junctions of heavily
truncated insertions. (b) Pre- and post- mutation site sequences for
MeCP2: Pre-integration panel shows the sequence at the L1 mutation site
as obtained from the human reference genome (GRCh37/hg19). A 58 nt
deletion was detected after the L1 mutation (marked in green within
box). Post-integration panel shows the 5' and 3' termini sequences of the
L1 mutation and flanking genomic region. L1PA2 sequence is marked in
red. The 49 additional nucleotides from an Alu are marked in grey. Micro-
homology with the pre-integration genomic region is denoted (under-
lined). Slashes represent L1PA2 sequence not shown. Lowercase
indicate mutations versus reference sequences. (c) MeCP2 L1 mutation
PCR validation: DNA extracted from different regions of the tumour
(denoted from A to G) was used as template for the amplification of
MeCP2 5'end L1 junction. No amplification was detected when water
was used as template (NTC). (d) Pre- and post- mutation site sequences
for EGFR: Pre-integration panel shows the sequence at the L1 insertion
site as obtained from the human reference genome (GRCh37/hg19). A
550 nt deletion was detected after the L1 mutation (marked in green
within box). Post-integration panel shows the 5' and 3' termini sequences
of the L1 mutation and flanking genomic region. L1-Ta sequence is
marked in red. Slashes represent genomic or L1-Ta sequence not shown.
Lowercase indicate mutations relative to reference sequences (L1-Ta,
human reference genome). Untemplated nucleotides are represented in
grey. (e) EGFR mutation site PCR validation: DNA extracted from different
regions of the tumour (denoted from A to G) was used as template for
Table 1 Published analyses of L1-associated mutations in brain tumours
Study Brain tumour types (sample count) Sequencing method L1 coverage (tumour) Potential somatic L1-associated
mutations (PCR validated)
Ref.
Iskow et al. GBM (5), medulloblastoma (5) L1-seq 3.6× - 6.4× 74 (0) [30]
Lee et al. GBM (16) WGS 39.2× 16 (0) [32]
Brennan et al. GBM (42) WGS 35.3× 0 (0) [6]
Helman et al. GBM (20) WGS 40.8× 0 (0) [35]
Tubio et al. Glioma cell line (1) WGS 42.6× 1 (0) [31]
Carreira et al. GBM (9), glioma (5) RC-seq 43.2×–231.0× 4 (2) –
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the amplification of the EGFR 5' end L1 junction. No amplification was
detected when water was used as template (NTC) (EPS 2005 kb)
Additional file 3: Figure S3. Copy number aberrations in the tumour
sample of patient #2 on chr4q12. (a) Detailed view of the 4q12 region
with aberrant and highly variable copy number changes in oncogenes
PDGFRA, KIT, and KDR (VEGFR2). (b) altered region in the context of
chromosome 4. Y-axis of both panels indicates the log10 fold-change in
counts per million (CPM), X-axis indicates position on the indicated
chromosome. Shaded regions indicate gaps in the chromosome
reference sequence. (PDF 133 kb)
Additional file 4: Figure S4. Copy number aberration of CDKN2A on
chromosome 9 in patient 2. (a) Detailed view of the CDKN2A region with
the regional single-copy deletion and focal deletion of both copies i
ndicated. (b) Altered region in the context of chromosome 9. Axes and
shading are as described for Additional file 3: Figure S3. (PDF 130 kb)
Additional file 5: Figure S5. Copy number aberration of MECP2 on
chromosome X in patient 2. (a) Detailed view of the MECP2 region with
the regional single-copy amplification indicated. (b) Altered region in the
context of chromosome X. Axes and shading are as described for
Additional file 3: Figure S3. (PDF 135 kb)
Additional file 6: Figure S6. Copy number aberration of EGFR,
CDKN2A, and RAB14 in patient 8. (a) Amplification of EGFR on
chromosome 7 (see also Fig. 2e). (b) Amplifications on chromosome 9
including CDKN2A and RAB14. (PDF 151 kb)
Additional file 7: Figure S2. Retrotransposition assay flow cytometry
gating parameters. Flow cytometry gating strategy for LN 229 cell line is
shown as an example. Cells were distinguished from debris based on
internal complexity (side scatter light area, SSC-A) and size (forward scatter
light area, FSC-A). To identify single cells only, the original population was
gated based on the size (FSC-A) and height (forward scatter light height,
FSC-H) of the cells. Propidium iodide staining was used to distinguish dead
and alive cells. GFP positive events were gated based on the absence of
GFP signal from the untransfected live cell population. Flow cytometry
analysis settings were established for untransfected cells and applied to
transfected cells. (EPS 2683 kb)
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growth factor receptor alpha gene; RC-seq: Retrotransposon capture
sequencing; RNP: Ribonucleoprotein particle; RT: Reverse transcriptase;
TP53: Tumour protein p53 gene; TPRT: Target-primed reverse transcription;
TSDs: Target site duplications; UTR: Untranslated region; VAF: Variant
allele fraction
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